교육신청

  • 전체전체
  • 특화 교육특화 교육
  • GCPGCP
  • 임상시험 코디네이터(CRC)임상시험 코디네이터
  • 임상시험 모니터요원(CRA)임상시험 모니터요원
  • 실시기관 품질보증담당자(QA)실시기관 품질보증담당자
  • 심사위원회 위원(IRB)심사위원회 위원
  • 관리약사(CRP)관리약사
  • 임상연구자(PI)임상연구자
  • 임상시험통계임상시험통계
  • 프로젝트 매니지먼트(PM)프로젝트 매니지먼트
  • 임상시험 데이터관리(DM)임상시험 데이터관리
  • 온라인온라인
  • 임상시험입문임상시험입문
  • 이전과정이전과정

Trends in Gene & Cell Therapy_공통보수

구분 온라인교육
카테고리온라인 > KoNECT International Conference_공통 > 2018 KoNECT International Conference
과정명Trends in Gene & Cell Therapy
신청기간 상시 교육기간 -
학습일수/시간 30 일 / 58 분 교육장소 미정
수강료 무료 교육정원인원제한없음
  • 소개
  • 목차
  • 교육일정
학습개요

Gene and Cell Therapy: How It Started, Where We Are, and What Is Next?

 

?Young Jik Kwon(University of California)

Among many modes of emerging therapies, gene and cell therapy has been of great interest recently as fully approved products start to step in the market. They share common technological fundamentals: Controlled biological functions via the molecular manipulation of genetic information, meaning that both therapies face similar challenges and need common breakthroughs in basic science. Despite tremendous potential impact on healthcare, the race in the field is still on going for several decades and many multi- dimensional barriers for clinical translation exist. In this talk, the beginning of the gene and cell therapy, key milestones and drawbacks in history, current status of the technology, and perspectives of the technology will be introduced and discussed, particularly in context of clinical translation and commercialization. By providing a macro view of the topic, it will allow the audience to grasp the insightful ideas about the exciting technology with uncertain fate.  

 

Current Status of Gene Therapy


Jae-Gyun Jeong(ViroMed Co., Ltd.)

Since the first human trial for gene therapy was conducted in 1989, 2,759 trials had been carried out for various diseases as of Nov 2017. Among them, a handful of products successfully entered the market. The first was “Glybera” which was approved in 2012 by the European regulatory authority, EMA. This product targeted a rare disease, lipoprotein lipase deficiency and gained huge attention because of several facts; the first gene therapy product marketed in advanced countries, the real proof showing the efficacy of gene therapy, and the most expensive drug in the world (its price tag was over 1 million dollars). Before we saw the first success story in this field, a tremendous number of trials experienced failures and frustration due to the lack of efficacy or severe adverse events. 2017 was another landmark year for gene therapy. Three new gene therapy products in the US and one product in Korea were approved. Still, there are people raising questions about whether this technology can guarantee both sufficient efficacy and safety. During my talk, I will focus on the features of gene therapy products currently available in the market and how they can provide treatment options to patients with unmet medical needs. 

 

Current Status of Gene Therapy

 

Kyungtak Nam(MFDS)

Regenerative medicine is a field that enables radical treatment by restoring human function by treating, replacing or regenerating damaged tissues and organs, and has been attracting attention as a technique to treat patients who are difficult to treat with current therapies such as rare incurable diseases.
In this presentation, I will introduce the status of the development of cell therapy and gene therapy products in Korea and the status of the related laws and regulations.
The commercialization of cell therapy products in Korea has more than 10 years of experience, and it is strong in that the government has a strong will to support the industry and has accumulated a lot of know-how about commercialization.
On the other hand, the biotechnology applied in the field of regenerative medicine is rapidly developing, but the regulation is limited in the traditional and comprehensive framework of medical law and pharmaceutical law, which does not reflect the specificity of regenerative medicine.
Advanced regenerative medicine and advanced biopharmaceuticals are developed in patient-customized form using living cells or tissues. Unlike traditional chemical drug, there are limitations in demonstrating safety and efficacy through animal experiments.
To reflect these considerations, the government will enact a 'Law on Advanced Regenerative Medicine and Advanced Biopharmaceuticals' that stipulates all the necessary items for safety management and support required for each phase of research and development of advanced biopharmaceuticals
In this presentation, I will introduce the status of the development of cell therapy and gene therapy products in Korea and the status of the related laws and regulations.? 

학습목표

1. Young Jik Kwon(University of California)

2. Jae-Gyun Jeong(ViroMed Co., Ltd.)

3. Kyungtak Nam(MFDS)

교육대상

상기 과정은 보수과정으로 직능별, 단계별 인정가능시간이 상이함으로 관련규정 '[별표1] 임상시험등 종사자별 교육과정 및 이수시간'을 꼭 확인하시기 바랍니다.

[별표 1]

임상시험등 종사자별 교육과정 및 이수시간

(5조 관련)

교육과정

해당 분야 실시경험이

없는 종사자

해당 분야 실시경험이 있는 종사자2)

신규자 교육과정

(우선교육시간)1)

심화 교육과정

보수 교육과정

 . 임상시험등 시험책임자3), 시험담당자4)

8시간 이상

(4시간 이상)

6시간 이상

4시간 이상

 . 심사위원회 위원

의사등3)

8시간 이상

(4시간 이상)

6시간 이상

4시간 이상

그 밖의 위원

12시간 이상

(6시간 이상)

6시간 이상

4시간 이상

 . 관리약사

8시간 이상

(4시간 이상)

6시간 이상

4시간 이상

 . 임상시험등 모니터요원

40시간 이상

(20시간 이상)

24시간 이상

8시간 이상

 . 임상시험등 코디네이터

 . 임상시험등 실시기관 품질보증 담당자

 . 임상시험등 업무 담당자5)

4시간 이상

(2시간 이상)

3시간 이상

2시간 이상

1) 규칙 제38조의23항 후단 및 제5조제2항에 따라 임상시험등 업무 경력이 없는 사람이 그 업무를 시작하기 전에 받아야 하는 교육시간을 말한다.

2) 보수교육과정은 평가를 생략할 수 있고, 해당 교육과정의 교육대상이면서 교육을 실시한 경우에는 교육시간을 이수시간으로 인정하며, 심포지엄, 워크숍, 온라인 교육 등으로 이수할 수 있으며, 이수시간의 최대 50/100까지 인정된다.

3) 의사 등이 시험책임자?시험담당자 교육과정에서 이수 받은 교육시간은 심사위원회 교육과정에서 이수 받은 교육시간으로 보며, 반대의 경우도 동일하게 적용한다.

4) 의약품 등의 안전에 관한 규칙[별표 4] 의약품 임상시험 관리기준 제2호코목에 따른 시험당당자(Subinvestigator)를 말한다.

5) 시험담당자(Subinvestigator), 관리약사, 임상시험등 코디네이터를 제외한 시험책임자의 위임 및 감독에 따라 임상시험등 업무를 담당하는 사람(임상병리사, 방사선사 등)을 말한다.

 

수료/과락 기준
평가기준 집합 출석율 온라인 진도율 시험 과제 토론 기타
배점비율 - 100.00% - - - -
과락기준 - 100% - - - -
Family Site